Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease

Wegrzyniak, Olivia; Rosestedt, Maria; Eriksson, Olof

doi:10.3390/ijms22147348

Cited by 11 publications

(5 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A potential drawback of PET technology is the requirement for an expensive infrastructure, such as a cyclotron, for on-site radionuclide production. In contrast, radiometals like 68 Ga can be produced by generators instead of cyclotrons, which makes them increasingly favored for diagnosing liver fibrosis [ 182 ]. Rosestedt et al.…”

Section: Available Molecular Imaging Modalities For Liver Fibrosismentioning

confidence: 99%

“…It should be borne in mind that PET and SPECT exhibit ionizing radiation, low spatial resolution, and lack of anatomical information. As compared to SPECT, PET offers greater sensitivity and utilizes more durable and adaptable tracers, but the high cost of cyclotron of PET limits its accessibility to wide patients [ 182 , 222 ]. As to FI, it has merits including high spatiotemporal resolution, noninvasive detection, real-time monitoring capabilities, and ease in operation.…”

Section: Available Molecular Imaging Modalities For Liver Fibrosismentioning

confidence: 99%

See 1 more Smart Citation

Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis

Chen,

Zhuang,

Jia

et al. 2024

Biomater Res

View full text Add to dashboard Cite

Liver fibrosis is a wound-healing response to chronic liver injury, which may lead to cirrhosis and cancer. Early-stage fibrosis is reversible, and it is difficult to precisely diagnose with conventional imaging modalities such as magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography, and ultrasound imaging. In contrast, probe-assisted molecular imaging offers a promising noninvasive approach to visualize early fibrosis changes in vivo, thus facilitating early diagnosis and staging liver fibrosis, and even monitoring of the treatment response. Here, the most recent progress in molecular imaging technologies for liver fibrosis is updated. We start by illustrating pathogenesis for liver fibrosis, which includes capillarization of liver sinusoidal endothelial cells, cellular and molecular processes involved in inflammation and fibrogenesis, as well as processes of collagen synthesis, oxidation, and cross-linking. Furthermore, the biological targets used in molecular imaging of liver fibrosis are summarized, which are composed of receptors on hepatic stellate cells, macrophages, and even liver collagen. Notably, the focus is on insights into the advances in imaging modalities developed for liver fibrosis diagnosis and the update in the corresponding contrast agents. In addition, challenges and opportunities for future research and clinical translation of the molecular imaging modalities and the contrast agents are pointed out. We hope that this review would serve as a guide for scientists and students who are interested in liver fibrosis imaging and treatment, and as well expedite the translation of molecular imaging technologies from bench to bedside.

show abstract

Section: Available Molecular Imaging Modalities For Liver Fibrosismentioning

confidence: 99%

Section: Available Molecular Imaging Modalities For Liver Fibrosismentioning

confidence: 99%

Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis

Chen,

Zhuang,

Jia

et al. 2024

Biomater Res

View full text Add to dashboard Cite

show abstract

“…The global incidence rate of NAFLD has been continuously increasing ( Wegrzyniak et al, 2021 ). NAFLD represents a wide range of liver diseases induced by metabolic stress, from simple fatty liver to liver cirrhosis.…”

Section: The Role Of Ferroptosis In Liver Diseasesmentioning

confidence: 99%

The Emerging Role of Ferroptosis in Liver Diseases

Chen¹,

Zhu²,

Zang³

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Ferroptosis is a newly discovered type of cell death mediated by iron-dependent lipid peroxide. The disturbance of iron metabolism, imbalance of the amino acid antioxidant system, and lipid peroxide accumulation are considered distinct fingerprints of ferroptosis. The dysregulation of ferroptosis has been intensively studied in recent years due to its participation in various diseases, including cancer, kidney injury, and neurodegenerative diseases. Notably, increasing evidence indicates that ferroptosis plays different roles in a wide spectrum of liver diseases. On the one hand, inhibiting ferroptosis may counteract the pathophysiological progression of several liver diseases, such as alcoholic liver injury, nonalcoholic steatosis hepatitis and fibrosis. On the other hand, inducing ferroptosis may restrict the emergence of secondary resistance to current medicines, such as sorafenib, for hepatocellular carcinoma (HCC) therapy. Here, we summarize the biological characteristics and regulatory signalling pathways of ferroptosis involved in liver disease. The current available medical agents targeting ferroptosis, including inducers or inhibitors applied in liver diseases, are also reviewed. This work aims to provide new insight into the emerging role of pathogenesis and therapeutic approaches for liver diseases.

show abstract

“…68 Ga-labeled FAPI-04 (a specific inhibitor of FAP) is used as a PET tracer for tumor diagnosis by visualizing desmoplastic reaction 3–5 . It also has the potential for nonmalignant diseases associated with tissue remodeling, including myocardial infarction, 6 sarcoidosis, chronic inflammation, 7 fibrosis of lung and liver, 8,9 rheumatoid arthritis, 10 and possibly also atherosclerosis 11,12 . Clinical application of 68 Ga-FAPI-04 PET in different diseases is being defined 13–15 …”

mentioning

confidence: 99%

Uterine Uptake of 68Ga-FAPI-04 in Uterine Pathology and Physiology

et al. 2022

View full text Add to dashboard Cite

Purpose: 68 Ga-labeled fibroblast activation protein inhibitor ( 68 Ga-FAPI-04) has been useful in the imaging of desmoplastic reaction in different tumors. As we have found that most female patients showed avid uterine uptake of 68 Ga-FAPI-04, we sought to further investigate the pathological and physiological uptake of 68 Ga-FAPI-04 characteristics in the uterus. Patients and Methods: We reviewed the image data of female patients who had undergone 68 Ga-FAPI-04 PET/MRI at our institute between May 22, 2020, and June 21, 2021. The characteristics of uterine uptake and clinical information were collected. The uterus with and without malignancy were compared. We further analyzed the relationship of age, uterus size, gynecological history, and 18 F-FDG uptake (if performed) with 68 Ga-FAPI-04 uptake. Results: Seventy-seven patients were included in this study. Much higher cervical 68 Ga-FAPI-04 accumulation was noticed in cervical cancer patients than in normal cases, and 37 more metastases were found in 68 Ga-FAPI-04 PET than that in 18 F-FDG. Uterine body malignancies displayed different uptake features. Two cases with the metastases to uterine body showed relative lower 68 Ga-FAPI-04 activity compared with their normal uteri. Of 67 patients without malignancy, lower 68 Ga-FAPI-04 uptake was noted in postmenopausal women than in reproductive and perimenopausal patients. The invasive operation or hysteromyoma may increase 68 Ga-FAPI-04 uptake. Conclusions: 68 Ga-FAPI-04 PET might be a promising method in cervical cancers. However, physiological uptake may limit its diagnostic value in uterine body malignancy. It should be noticed that the metastatic lesion in the uterus may show relative lower uptake of 68 Ga-FAPI-04 compared with the rest of the uterus. Age, fibroids, and uterine volume may influence 68 Ga-FAPI-04 uptake in the uterus. More patients with various uterine diseases could be involved to provide more differential diagnostic information.

show abstract

Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease

Cited by 11 publications

References 74 publications

Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis

Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis

The Emerging Role of Ferroptosis in Liver Diseases

Uterine Uptake of 68Ga-FAPI-04 in Uterine Pathology and Physiology

Contact Info

Product

Resources

About